A detailed history of Boothbay Fund Management, LLC transactions in Incyte Corp stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 4,534 shares of INCY stock, worth $331,843. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,534
Holding current value
$331,843
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $259,934 - $311,077
4,534 New
4,534 $299,000
Q1 2023

May 15, 2023

SELL
$70.23 - $86.01 $4.78 Million - $5.85 Million
-68,027 Reduced 94.05%
4,300 $310,000
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $89,215 - $111,698
-1,328 Reduced 1.8%
72,327 $5.81 Million
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $4.87 Million - $6.1 Million
73,655 New
73,655 $4.91 Million
Q3 2021

Nov 15, 2021

SELL
$68.67 - $84.02 $66,060 - $80,827
-962 Reduced 22.66%
3,284 $226,000
Q2 2021

Aug 16, 2021

SELL
$79.87 - $87.53 $18,689 - $20,482
-234 Reduced 5.22%
4,246 $357,000
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $340,569 - $450,240
4,480 New
4,480 $364,000
Q3 2020

Nov 16, 2020

SELL
$85.07 - $109.69 $2.4 Million - $3.1 Million
-28,250 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$74.18 - $108.93 $626,821 - $920,458
-8,450 Reduced 23.02%
28,250 $2.94 Million
Q1 2020

May 15, 2020

BUY
$63.18 - $85.97 $2.32 Million - $3.16 Million
36,700 New
36,700 $2.69 Million
Q1 2019

May 15, 2019

SELL
$63.56 - $88.17 $586,404 - $813,456
-9,226 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$58.5 - $69.94 $9,067 - $10,840
155 Added 1.71%
9,226 $587,000
Q3 2018

Nov 14, 2018

SELL
$61.75 - $74.23 $492,888 - $592,503
-7,982 Reduced 46.81%
9,071 $627,000
Q2 2018

Aug 14, 2018

BUY
$60.85 - $83.98 $1.04 Million - $1.43 Million
17,053 New
17,053 $1.14 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.